ArticleInternational journal of nanomedicine2019
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of different drugs in patients with HER2-positive gastric cancer: network meta-analysis.Systematic reviews · 2025Pooled it
- Investigating the potential application of organic and non-organic nanoparticles for gastric cancer treatment: An evidence-based review.Archives of Razi Institute · 2024Pooled it
- Prospects and challenges in intracellular delivery of therapeutic proteins.Pharmacological reports : PR · 2026Review
- Time-Resolved SAXS Studies During the Synthesis of Hydrolytically Degradable Poly(ε-caprolactone)-Poly(N,N'-dimethylacrylamide) Diblock Copolymer Nanoparticles in Aqueous Media.Angewandte Chemie (International ed. in English) · 2026Article
- Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025Review
- Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers · 2025Review
- Multifunctional Magnetic Ionic Liquid-Carbon Nanohorn Complexes for Targeted Cancer Theranostics.Small science · 2025Article
- Engineered PEG-PCL nanoparticles enable sensitive and selective detection of sodium dodecyl sulfate: a qualitative and quantitative analysis.Beilstein journal of nanotechnology · 2025Article
- Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization.BioImpacts : BI · 2025Review
- Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.Frontiers in bioengineering and biotechnology · 2025Review
- Analytical Techniques for Characterizing Tumor-Targeted Antibody-Functionalized Nanoparticles.Life (Basel, Switzerland) · 2024Review
- Systematic Investigation of Cellular Response to Hydroxyl Group Orientation Differences on Gold Glyconanoparticles.ACS omega · 2023Article
- Enhancing the Treatment of Uncontrolled Inflammation through the Targeted Delivery of TPCA-1-Loaded Nanoparticles.Pharmaceutics · 2023Article
- All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.Bioactive materials · 2023Article
- Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy.Journal of nanobiotechnology · 2023Review
- Article
- Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics.Beilstein journal of nanotechnology · 2023Review
- Nanoparticles and Nanomaterials-Based Recent Approaches in Upgraded Targeting and Management of Cancer: A Review.Cancers · 2022Review
- Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?Pharmaceutics · 2022Review
- Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDocetaxel (DOC) is widely used as a chemotherapy drug for various tumors, including gastric cancer (GC), but the clinical application of DOC has been limited due to the hydrophobicity of the drug. We aimed to formulate a multifunctional nanoparticle (NP) system to reduce the side effects of the chemotherapy agent, to promote synergistic therapeutic effects, and to achieve targeted delivery of the therapy.
methodsThe polyethylene glycol-poly(ε-caprolactone) NPs (PEG-PCL NPs) were prepared by a ring opening copolymerization technique and were then conjugated with a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The effects of the surface coating on particle size, size distribution, zeta potential, drug encapsulation efficiency, loading capacity, and the drug release kinetics were investigated. By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs.
resultsThe characterization of the structure and biological functions of DOC-PEG-PCL-mAb NPs was investigated in vitro. X-ray photoelectron spectroscopy validated the presence of the PD-L1 mAbs on the NP surface. The cellular uptake analysis showed that the antibody-conjugated NPs achieved significantly higher cellular uptake. The results of an in vitro cytotoxicity experiment on three GC lines further proved the targeting effects of the antibody conjugation. In addition, we found that the DOC-PEG-PCL-mAb NPs induced cell apoptosis and enhanced G2-M arrest in cancer cells, indicating the inhibition of microtubule synthesis. When compared with the control groups, DOC-PEG-PCL-mAb NPs are more effective in inhibiting PD-L1 expression in GC cells.
conclusionOur results reported here highlight the biological and clinical potential of DOC-PEG-PCL-mAb NPs using PD-L1 mAbs in GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.